SEMA4G

Across TCGA pan-cancer cohorts, SEMA4G Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SEMA4G data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SEMA4G Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEMA4G expression acts as an unfavorable survival marker.

LUSC, KICH, and LIHC are the cancer types where SEMA4G Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.153	0.722	<.001	44	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
PRAD	DFS	Median	All	0.712	0.936	.001	6	view →
SKCM	DFS	Median	III,IV	0.058	0.648	.001	3	view →
BRCA	OS	Median	All	0.842	0.963	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SEMA4G–LUSC (DFS)

Open the LUSC breakdown →